A Phase 2 clinical trial of FS-1502 in China in patients with a range of solid tumours

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab monomethyl auristatin F (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours
Focus Therapeutic Use
Sponsors Shanghai Fosun Pharmaceutical

04 Jun 2024 Results ( At data cutoff Dec 24,2023, n=4) assessing safety and efficacy of FS-1502 in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology
26 Oct 2023 New trial record
21 Oct 2023 According to an Iksuda Therapeutics media release, company holds licence to the ADC (Aantibody Drug Conjugate; IKS014 is the first of Iksuda's ADCs) in Greater China where it is designated FS-1502. Fosun is currently conducting Phase 2 clinical trial in China in patients with a range of solid tumours.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com